Frankfurt
21.09.26 | 08:08
0,644 Euro
-0,62 % -0,004
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell Agreements | 395 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.09. | AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15 | 256 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 27.08. | AlzeCure Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference on September 2 | 489 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 26.08. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - June 2026 | 159 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June 2026 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"During... ► Artikel lesen | |
| 18.08. | AlzeCure Pharma: AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly | 1.480 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 12.08. | AlzeCure Pharma: AlzeCure Receives a Total Upfront Payment of USD 12 million and Completes the Initial Transaction with QuantumCell | 522 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 12, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 03.08. | AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell | 372 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 3, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) ("AlzeCure" or the "Company") announced in a press release on 1 July 2026 that the Company had entered... ► Artikel lesen | |
| 02.07. | AlzeCure Pharma: Final Outcome of AlzeCure's Rights Issue | 605 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | 3 | Pharmaceutical Technology | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | 4 | FierceBiotech | ||
| 01.07. | AlzeCure Pharma Aktie schießt nach milliardenschwerem Lizenzdeal in die Höhe | 5 | Investing.com Deutsch | ||
| 01.07. | AlzeCure-Aktie: Milliarden-Deal treibt Kurs auf Hoch seit 2022 | 1 | Investing.com Deutsch | ||
| 01.07. | AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project | 675 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 29.06. | Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026 | 686 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's | 604 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: The subscription period in AlzeCure Pharma's Rights Issue begins today | 498 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 15.06. | Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 303 | GlobeNewswire | With effect from June 16, 2026, the subscription rights in AlzeCure Pharma AB will be traded on First North Growth Market. Trading will continue up until and including June 25, 2026.
... ► Artikel lesen | |
| 10.06. | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement | 6 | Pharmaceutical Technology | ||
| 10.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.06.2026 | 343 | Xetra Newsboard | Das Instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.06.2026 und ex Kapitalmassnahme am 11.06.2026 The instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY... ► Artikel lesen | |
| 09.06. | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | 8 | FierceBiotech |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 441,00 | -0,34 % | Olympic skier Lindsey Vonn joins up with Vertex for pain campaign | ||
| VIATRIS | 14,970 | +1,53 % | Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? | ||
| ALTIMMUNE | 2,920 | +3,00 % | Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,000 | 0,00 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| OPKO HEALTH | 1,390 | -4,79 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| JAGUAR HEALTH | 2,710 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenDE000A2YNT30 Alzchem Group AG 16.09.2026 DE000A41YHG1 Alzchem Group AG 17.09.2026 Tausch 1:1AU0000090060 Europa Metals... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 14,540 | -0,82 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,730 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs | Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunitiesEncinitas... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 4,766 | +2,14 % | Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating | ||
| LIPOCINE | 2,140 | 0,00 % | Lipocine Inc.: Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression | Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial
Approximately 120 participants with severe... ► Artikel lesen | |
| PHOTOCURE | 4,795 | 0,00 % | Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II | OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 24,200 | +0,41 % | Eurobio Scientific: First half of 2026, Continuation of the strategic transformation | FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION First-half revenue up 5% to €84.5 millionContinuation of the Group's strategy: Proprietary products: 37% of revenueInternational expansion:... ► Artikel lesen | |
| MEDICURE | 1,640 | +1,86 % | Medicure, Inc.: Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress | WINNIPEG, MB / ACCESS Newswire / September 8, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| IM CANNABIS CORP | 4,200 | 0,00 % | IM Cannabis Stock Surges 247% | ||
| BAYER | 48,550 | -1,94 % | Bayer schließt Kapitallösung für Verhütungsgeschäft ab |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,62 % bei einem Aktienkurs von 0,644 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.